Literature DB >> 25400422

Inhibition of PI3K/Akt/mTOR signaling pathway enhances the sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin in vitro.

Yunlang Cai1, Xiaoqiang Tan1, Jun Liu1, Yang Shen1, Di Wu1, Mulan Ren1, Peilin Huang1, Dandan Yu1.   

Abstract

The activation of the PI3K/AKT/mTOR pathway plays a key role in ovarian cancer tumorigenesis, progression and chemotherapy resistance. This study aimed to explore the possible mechanism that PI-103, a dual inhibitor of phosphatidylinositide 3-kinase and mTOR, enhances the sensitivity of SKOV3/DDP ovarian cancer cell line to cisplatin chemotherapy. The results showed that PI-103 could significantly increase the sensitivity of SKVO3/DDP cells to cisplatin through inhibiting the activation of PI3K/Akt/mTOR signaling pathway and inducing cell cycle arrest and apoptosis.

Entities:  

Keywords:  PI3K/AKT/mTOR; cisplatin; ovarian cancer

Year:  2014        PMID： 25400422      PMCID： PMC4220257          DOI： 10.3978/j.issn.1000-9604.2014.08.20

Source DB:  PubMed          Journal:  Chin J Cancer Res        ISSN： 1000-9604            Impact factor:   5.087


  21 in total

1.  Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells.

Authors:  Dong-Jun Peng; Juan Wang; Jun-Ying Zhou; Gen Sheng Wu
Journal:  Biochem Biophys Res Commun       Date:  2010-03-07       Impact factor: 3.575

2.  Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line.

Authors:  Sooyong Lee; Eui-Ju Choi; Changbae Jin; Dong-Hyun Kim
Journal:  Gynecol Oncol       Date:  2005-04       Impact factor: 5.482

Review 3.  PI3K/Akt/mTOR pathway as a target for cancer therapy.

Authors:  Daniel Morgensztern; Howard L McLeod
Journal:  Anticancer Drugs       Date:  2005-09       Impact factor: 2.248

4.  PI3K inhibitors prime neuroblastoma cells for chemotherapy by shifting the balance towards pro-apoptotic Bcl-2 proteins and enhanced mitochondrial apoptosis.

Authors:  A Bender; D Opel; I Naumann; R Kappler; L Friedman; D von Schweinitz; K-M Debatin; S Fulda
Journal:  Oncogene       Date:  2010-09-20       Impact factor: 9.867

Review 5.  Genetic alterations in signaling pathways in melanoma.

Authors:  Frank G Haluska; Hensin Tsao; Helen Wu; Frank S Haluska; Alexander Lazar; Vikas Goel
Journal:  Clin Cancer Res       Date:  2006-04-01       Impact factor: 12.531

6.  Characterization of structurally distinct, isoform-selective phosphoinositide 3'-kinase inhibitors in combination with radiation in the treatment of glioblastoma.

Authors:  Jack S Chen; Linda J Zhou; Michal Entin-Meer; Xiaodong Yang; Mila Donker; Zachary A Knight; William Weiss; Kevan M Shokat; Daphne Haas-Kogan; David Stokoe
Journal:  Mol Cancer Ther       Date:  2008-04       Impact factor: 6.261

7.  Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species.

Authors:  Maria Wartenberg; Frederike C Ling; Markus Müschen; Florian Klein; Helmut Acker; Max Gassmann; Kerstin Petrat; Volker Pütz; Jürgen Hescheler; Heinrich Sauer
Journal:  FASEB J       Date:  2003-01-02       Impact factor: 5.191

8.  Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.

Authors:  Maarten L Janmaat; Frank A E Kruyt; José A Rodriguez; Giuseppe Giaccone
Journal:  Clin Cancer Res       Date:  2003-06       Impact factor: 12.531

9.  Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones.

Authors:  Andrea Cavazzoni; Mara A Bonelli; Claudia Fumarola; Silvia La Monica; Kinda Airoud; Ramona Bertoni; Roberta R Alfieri; Maricla Galetti; Stefano Tramonti; Elena Galvani; Adrian L Harris; Lesley-Ann Martin; Daniele Andreis; Alberto Bottini; Daniele Generali; Pier Giorgio Petronini
Journal:  Cancer Lett       Date:  2012-04-03       Impact factor: 8.679

Review 10.  The importance of the PI3K/AKT/MTOR pathway in the progression of ovarian cancer.

Authors:  Zachary C Dobbin; Charles N Landen
Journal:  Int J Mol Sci       Date:  2013-04-15       Impact factor: 5.923
View more
  19 in total

1.  Establishment of specific cytotoxic T lymphocyte culture system and its inhibitory effect on ovarian cancer.

Authors:  Mingxing Sui; Lihui Si; Tianmin Xu; Manhua Cui
Journal:  Oncol Lett       Date:  2016-09-28       Impact factor: 2.967

2.  Interference of P-REX2a may inhibit proliferation and reverse the resistance of SGC7901 cells to doxorubicin.

Authors:  Yaowei Ai; Qiaohui Zhou; Ling Li; Zhihong Pan; Mingwen Guo; Jingbo Han
Journal:  Oncol Lett       Date:  2017-12-27       Impact factor: 2.967

3.  TRAIL enhances quinacrine-mediated apoptosis in breast cancer cells through induction of autophagy via modulation of p21 and DR5 interactions.

Authors:  Sarita Das; Anmada Nayak; Sumit Siddharth; Deepika Nayak; Satya Narayan; Chanakya Nath Kundu
Journal:  Cell Oncol (Dordr)       Date:  2017-09-21       Impact factor: 6.730

4.  PI3K Inhibition Sensitize the Cisplatin-resistant Human Ovarian Cancer Cell OVCAR3 by Induction of Oxidative Stress.

Authors:  Sahar Baghal-Sadriforoush; Morteza Bagheri; Isa Abdi Rad; Fattah Sotoodeh Nejadnematalahi
Journal:  Rep Biochem Mol Biol       Date:  2022-01

5.  Cardamonin enhances the anti-proliferative effect of cisplatin on ovarian cancer.

Authors:  Peiguang Niu; Daohua Shi; Shusheng Zhang; Yanting Zhu; Jintuo Zhou
Journal:  Oncol Lett       Date:  2018-01-08       Impact factor: 2.967

6.  MiR-221/222 promote chemoresistance to cisplatin in ovarian cancer cells by targeting PTEN/PI3K/AKT signaling pathway.

Authors:  Zeinab Amini-Farsani; Mohammad Hossein Sangtarash; Mehdi Shamsara; Hossein Teimori
Journal:  Cytotechnology       Date:  2017-09-08       Impact factor: 2.058

7.  Prognostic Significance of mTOR and PTEN in Patients with Esophageal Squamous Cell Carcinoma.

Authors:  Jianjun Lu; You Pan; Xin Xia; Yong Gu; Yiyan Lei
Journal:  Biomed Res Int       Date:  2015-08-18       Impact factor: 3.411

8.  S6Ks isoforms contribute to viability, migration, docetaxel resistance and tumor formation of prostate cancer cells.

Authors:  Camila L Amaral; Lidia B Freitas; Rodrigo E Tamura; Mariana R Tavares; Isadora C B Pavan; Marcio C Bajgelman; Fernando M Simabuco
Journal:  BMC Cancer       Date:  2016-08-05       Impact factor: 4.430

9.  Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer.

Authors:  Rebecca C Arend; Angelina I Londoño-Joshi; Abhishek Gangrade; Ashwini A Katre; Chandrika Kurpad; Yonghe Li; Rajeev S Samant; Pui-Kai Li; Charles N Landen; Eddy S Yang; Bertha Hidalgo; Ronald D Alvarez; John Michael Straughn; Andres Forero; Donald J Buchsbaum
Journal:  Oncotarget       Date:  2016-12-27

10.  Complement C1q stimulates the progression of hepatocellular tumor through the activation of discoidin domain receptor 1.

Authors:  Ji-Hyun Lee; Barun Poudel; Hyeon-Hui Ki; Sarmila Nepali; Young-Mi Lee; Jeon-Soo Shin; Dae-Ki Kim
Journal:  Sci Rep       Date:  2018-03-20       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.